Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain

ABSTRACT

Pentoxifylline [PTX] is a non-specific cytokine inhibitor that has been reported to attenuate pain in several animal models and humans. However, long-term therapeutic effects of PTX on neuropathic pain in a rat model of chronic constriction injury [CCI] are not completely clear. This study was conducted to examine the effect of long-term administration of PTX on neuropathic pain in rats. Neuropathic pain was induced by sciatic nerve ligation using of CCI model in rats. Rats were randomly assigned into sham, CCI-saline treated, and CCI-PTX treated [30 or 60 mg/kg ip] groups. PTX or saline administered at 30 min before CCI and daily for 14 days post-CCI. At the days of 3, 7, 11 and 14 following CCI, by using standard methods effects of thermal hyperalgesia, thermal and mechanical allodynia in all groups were examined using the standard methods. The CCI-saline treated group showed a significant increase in mechanical and thermal allodynia, and thermal hyperalgesia as compared with the sham group in the tested days. Administration of the higher dose of PTX [60 mg/kg/day], but not the lower dose [30 mg/kg/day] significantly reduced mechanical and thermal allodynia, as compared with the CCI-saline treated group on days of 3, 7, 11 and 14 [all P values<0.001]. Also, both doses of PTX significantly reduced thermal hyperalgesia as compared with the CCI-saline treated group on these days [all P values<0.001]. Results of this study show that chronic administration of PTX reduces the neuropathic pain in a rat model of CCI. Thus, this drug may have a therapeutic application in the treatment and management of neuropathic pain in humans